Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.
Intrahepatic Cholangiocarcinoma (Icc)
DRUG: Teripalimab|DRUG: Gemcitabine + Cisplatin|PROCEDURE: Surgery
1-year recurrence-free survival rate, 1 year
1-year OS, 1 year|2-year OS, 2-year|ORR, 1 year|DCR, 1 year|R0 resection rate, 1 year|30 day postoperative complication rate, 1 year|Occurrence of adverse reactions, 1 year
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.